About
Our Mission
Leadership
Partners
Our Technologies
TALEN® Technology
Gene Editing
PulseAgile Technology
Patents
Pipeline
Products
Clinical Indications
Manufacturing
Investors
Press Releases
Corporate presentation & ESG report
Scientific Presentations
Scientific Publications
Events and Webcasts
2021 Cellectis Innovation Days
Stock Information
Corporate Governance
Governance Documents
Board of Directors & Committee Members
Shareholders Meeting
SEC Filings
Contact
IR Inquiries
Email Alerts
Investor FAQ
Careers
Our Culture
Job Opportunities
Contact us
fr
Press Releases
Our latest news and press releases
Press releases
Corporate presentation
Scientific Presentations
Scientific Publications
Events and webcasts
Stock information
SEC filings
Financial Statements
Regulated information
Voting Rights & Share Capital
ATM Program
General meetings
Governance
The board and committee members
Corporate governance documents
FAQ
IR Inquiry
All
2024
2023
2022
2021
2020
12
Jun 2024
10:27 E.S.T.
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
Read more
04
Jun 2024
11:30 E.S.T.
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
Read more
29
May 2024
16:30 E.S.T.
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
Read more
28
May 2024
16:30 E.S.T.
Cellectis Reports Financial Results for First Quarter 2024
Read more
24
May 2024
22:30 E.S.T.
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
Read more
06
May 2024
02:05 E.S.T.
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
Read more
Prev
1
2
3
4
Next